Acute myocardial infarction Heart attack
Conditions
Interventions
Main trial:
No treatment or 1dd 80mg aspirin. Repeated measurements of platelet function
testing via venapuncture.
Sub-study:
No intervention, purely observetional. Repeated measurements of platel
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in the main-trial, a subject must meet all of the following criteria: Primary clinical diagnosis of pneumonia OR Primary clinical diagnosis of invasive urinary tract infection OR Primary clinical diagnosis of cutaneous infection AND 18 years or older on the date of hospital presentation AND Hospitalization for at least 24 hours AND Having received at least 1 dose of antibiotics within 48 hours of admission. In order to be eligible to participate in the sub-study, a subject must meet all of the following criteria: Primary clinical diagnosis of pneumonia OR Primary clinical diagnosis of invasive urinary tract infection OR Primary clinical diagnosis of cutaneous infection AND 18 years or older on the date of hospital presentation AND Hospitalization for at least 24 hours AND Having received at least 1 dose of antibiotics within 48 hours of admission AND Known stable cardiovascular disease. Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease, or previous myocardial infarction (>12 months). AND Chronic usage of 80 mg of non-enteric coated acetylsalicylic acid once daily in the morning.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in the main-trial: - Active metastatic cancer (c.q. malignancy) - Allergy to salicylate - Platelet count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFA-200 parameters: closure time, flow slope, maximum rate of occlusion and area under the curve TBX2 serum levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet- , reticulated platelet- , leucocyte count and haemoglobin level as a possible effect modifying parameter. | — |
Countries
Netherlands
Outcome results
None listed